Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

117
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
117
Cancer Survival Analysis01:21

Cancer Survival Analysis

336
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
336
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

168
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
168
Skin Cancer01:30

Skin Cancer

4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K
Actuarial Approach01:20

Actuarial Approach

70
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
70
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Breslow Density Ability To Predict Melanoma Survival: Should It Be Used In Clinical Practice?
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Breslow Density Ability To Predict Melanoma Survival: Should It Be Used In Clinical Practice?

Related Experiment Video

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

15.7K

Breslow density ability to predict melanoma survival: should it be used in clinical practice?

Pedro Gil-Pallares1,2, Olalla Figueroa-Silva1,2, Laura Taboada-Paz1

  • 1Department of Dermatology, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.

Clinical and Experimental Dermatology
|July 27, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Breslow density (BD) is a novel prognostic biomarker for melanoma. This study found BD ≥ 65% significantly predicts lower survival rates, offering valuable prognostic information comparable to Breslow thickness (BT).

More Related Videos

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.4K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

2.9K

Related Experiment Videos

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

15.7K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.4K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

2.9K

Area of Science:

  • Oncology
  • Dermatopathology
  • Cancer Research

Background:

  • Breslow density (BD) is an emerging histopathological prognostic biomarker for melanoma.
  • It estimates melanoma tumor volume, providing novel insights into disease progression.

Purpose of the Study:

  • To evaluate Breslow density (BD) as a predictor of patient survival.
  • To assess BD's prognostic value for overall survival (OS), disease-free survival (DFS), melanoma-specific survival (MSS), and metastasis-free survival (MFS).

Main Methods:

  • Retrospective observational study of 107 invasive melanoma patients.
  • Kaplan-Meier and Log-rank tests for 10-year survival analysis.
  • Receiver operating characteristic (ROC) curves to compare BD and Breslow thickness (BT) predictive abilities.

Main Results:

  • Patients with BD ≥ 65% exhibited significantly lower survival rates (log-rank test P < 0.001).
  • BD demonstrated higher predictive accuracy (AUC) than BT for OS, DFS, and MFS.
  • Absolute BD showed the highest predictive value for MSS.

Conclusions:

  • Breslow density (BD) is a simple, valuable, and inexpensive histopathological feature.
  • BD provides additional prognostic information beyond standard melanoma staging.
  • BD shows comparable 10-year survival prediction ability to Breslow thickness (BT).